Evidence map›Paper›PMID 34535769›Full record

ArticleOncogene2021

Identification of mutations that cooperate with defects in B cell transcription factors to initiate leukemia.

Lynn M Heltemes-Harris, Gregory K Hubbard, Rebecca S LaRue, Sarah A Munro, Rendong Yang, Christine M Henzler, Timothy K Starr, Aaron L Sarver, Steven M Kornblau, Michael A Farrar

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncogene, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Lynn M Heltemes-HarrisCenter for Immunology, University of Minnesota, Minneapolis, MN, 55455, USA.
Gregory K HubbardCenter for Immunology, University of Minnesota, Minneapolis, MN, 55455, USA.
Rebecca S LaRueMinnesota Supercomputing Institute, University of Minnesota, Minneapolis, MN, 55455, USA.
Sarah A MunroMinnesota Supercomputing Institute, University of Minnesota, Minneapolis, MN, 55455, USA.
Rendong YangMinnesota Supercomputing Institute, University of Minnesota, Minneapolis, MN, 55455, USA.ORCID 0000-0002-9512-2240
Christine M HenzlerMinnesota Supercomputing Institute, University of Minnesota, Minneapolis, MN, 55455, USA.
Timothy K StarrMasonic Cancer Center, University of Minnesota, Minneapolis, MN, 55455, USA.ORCID 0000-0002-6308-3451
Aaron L SarverMasonic Cancer Center, University of Minnesota, Minneapolis, MN, 55455, USA.
Steven M KornblauDepartment of Leukemia, The University of Texas, M.D. Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-5990-9548
Michael A FarrarCenter for Immunology, University of Minnesota, Minneapolis, MN, 55455, USA. farra005@umn.edu.ORCID 0000-0002-5569-0366
University of Minnesota · USThe University of Texas MD Anderson Cancer Center · USUniversity of Minnesota Medical Center · US

Funding

Women's CancerP30CA077598 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Jeffrey S. Miller · 1998 to 2026
$100.4M
University of Texas M.D. Anderson Cancer SPORE-LeukemiaP50CA100632 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI SHPALL, ELIZABETH J · 2003 to 2023
$43.7M
Pre-BCR and STAT5 Signaling in Acute Lymphoblastic LeukemiaR01CA232317 · NCI · UNIVERSITY OF MINNESOTA · PI FARRAR, MICHAEL ARCHIBALD · 2019 to 2023
$1.9M
Bioinformatics approaches to solve the "Missing Driver" problem in solid tumorsR50CA211249 · NCI · UNIVERSITY OF MINNESOTA · PI SARVER, AARON L · 2016 to 2020
$565k
Genetically Modified Natural Killer Cells for Cancer ImmunotherapyR21CA216652 · NCI · UNIVERSITY OF MINNESOTA · PI MORIARITY, BRANDEN S · 2018 to 2019
$362k
NCI NIH HHS P30 CA077598NCI NIH HHS P50 CA100632NCI NIH HHS R01 CA232317NCI NIH HHS R21 CA216652NCI NIH HHS R50 CA211249
6 · The paper itself

Abstract

The transcription factors PAX5, IKZF1, and EBF1 are frequently mutated in B cell acute lymphoblastic leukemia (B-ALL). We demonstrate that compound heterozygous loss of multiple genes critical for B and T cell development drives transformation, including Pax5

Indexed as

MutationAnimalsGain of Function MutationGenetic TestingHumansLoss of Function MutationMicePAX5 Transcription FactorPrecursor B-Cell Lymphoblastic Leukemia-LymphomaSequence Analysis, RNASignal TransductionTrans-ActivatorsTranscription FactorsTransposasesEBF1 protein, humanPAX5 protein, humanPAX5 Transcription Factorsleeping beauty transposase, humanTrans-ActivatorsTranscription FactorsTransposases

Identifiers

PMID34535769
PMCPMC8556320
OpenAlexW3200368200

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.